DDrare: Database of Drug Development for Rare Diseases

Skincerity plus sirolimus/rapamycin (DrugBank: Sirolimus, Rapamycin)

2 diseases

ID	Disease name (Link within this page)	Number of trials
34	Neurofibromatosis	1
158	Tuberous sclerosis	1

34. Neurofibromatosis [ 120 clinical trials, 182 drugs, (DrugBank: 72 drugs), 84 drug target genes, 194 drug target pathways]

Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 120 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01031901 (ClinicalTrials.gov)	December 2009	10/12/2009	Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)	Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1	Tuberous Sclerosis;Neurofibromatoses;Angiofibroma;Neurofibroma	Drug: Skincerity;Drug: Skincerity plus sirolimus/rapamycin;Drug: Skinercity plus sirolimus/rapamycin	The University of Texas Health Science Center, Houston	Society for Pediatric Dermatology	Completed	13 Years	N/A	Both	52	Phase 1	United States

158. Tuberous sclerosis [ 100 clinical trials, 62 drugs, (DrugBank: 16 drugs), 35 drug target genes, 115 drug target pathways]

Searched query = "Tuberous sclerosis", "Tuberous sclerosis complex"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 100 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01031901 (ClinicalTrials.gov)	December 2009	10/12/2009	Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)	Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1	Tuberous Sclerosis;Neurofibromatoses;Angiofibroma;Neurofibroma	Drug: Skincerity;Drug: Skincerity plus sirolimus/rapamycin;Drug: Skinercity plus sirolimus/rapamycin	The University of Texas Health Science Center, Houston	Society for Pediatric Dermatology	Completed	13 Years	N/A	Both	52	Phase 1	United States